$5.55-5.7%Nov 11 close
Figures through September 30, 2026, from the 10-Q filed November 13, 2026
Just reported
From Lifeward Ltd.'s results release of November 13, 2026; its quarterly report has since been filed.
Actual
$5.4M
-12% y/y
-18% q/q
Guided
—
No guide given
Actual
-$1.32
Guided
—
No guide given
Actual
-$6M
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $5.4M | $6.2M | -12.38% |
| Profit | -$5.1M | -$3.2M | -59.37% |
| Profit per share | -$1.32 | -$2.37 | +44.30% |
| Free Cash Flow | -$6.4M | -$3.8M | -66.16% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Lifeward Ltd. reported on November 13, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“The third quarter was a transitional quarter for Lifeward, marked by continued AlterG growth as we move into the advanced stages of transitioning ReWalk to a channel-partner distribution model,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Lifeward is a global innovator focused on advancing medical technologies and biomedical solutions that improve lives. The Company’s established portfolio includes market-leading neurorehabilitation technologies such as the ReWalk® Exoskeleton, AlterG® Anti-Gravity systems, and MyoCycle® FES System. These solutions span the continuum of care in physical rehabilitation and recovery, deploying the most advanced robotics and AI technologies to restore full health and quality of life to a broadening patient population. The Company is now executing a strategic evolution into a diversified biomedical company, expanding beyond rehabilitation and into high-value therapeutic platforms. This includes its Protein Oral Delivery (POD™) platform, designed to enable oral delivery of biologic drugs, with lead candidate ORMD-0801 (oral insulin) targeting a large and underserved diabetes market. Lifeward has operations in the United States, Israel, and Germany.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Lifeward Ltd.’s Item 2.02 8-K filed November 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.